tiprankstipranks
Insmed (DE:IM8N)
XETRA:IM8N
Germany Market
IM8N
Insmed
RESEARCH TOOLSreports

Insmed (IM8N) Stock Forecast & Price Target

9 Followers
See the Price Targets and Ratings of:

IM8N Analyst Ratings

Strong Buy
19Ratings
Strong Buy
19 Buy
0 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Insmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IM8N Stock 12 Month Forecast

Average Price Target

€173.81
▲(89.22% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is €173.81 with a high forecast of €210.07 and a low forecast of €146.10. The average price target represents a 89.22% change from the last price of €91.86.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"€88","211":"€211","118.75":"€118.8","149.5":"€149.5","180.25":"€180.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":210.07440882,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€210.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":173.81327972555553,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€173.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":146.10113206,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€146.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,118.75,149.5,180.25,211],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.59,98.85803144769231,108.12606289538462,117.39409434307692,126.66212579076924,135.93015723846153,145.19818868615386,154.46622013384615,163.73425158153844,173.00228302923077,182.2703144769231,191.53834592461538,200.80637737230768,{"y":210.07440882,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.59,96.06871382504274,102.54742765008547,109.0261414751282,115.50485530017093,121.98356912521368,128.4622829502564,134.94099677529914,141.41971060034186,147.8984244253846,154.37713825042732,160.85585207547007,167.3345659005128,{"y":173.81327972555553,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.59,93.93701015846155,98.28402031692308,102.63103047538462,106.97804063384615,111.32505079230769,115.67206095076924,120.01907110923077,124.36608126769231,128.71309142615385,133.06010158461538,137.40711174307694,141.75412190153847,{"y":146.10113206,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":93.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.59,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€210.07Average Price Target€173.81Lowest Price Target€146.10
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:IM8N
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€190.19
Buy
107.04%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)
Truist Financial Analyst forecast on DE:IM8N
Danielle Brill
Truist Financial
Truist Financial
€159.93→€168.58
Buy
83.52%
Upside
Reiterated
08/10/26
Truist Financial Remains a Buy on Insmed (INSM)
J.P. Morgan Analyst forecast on DE:IM8N
Jessica Fye
J.P. Morgan
J.P. Morgan
€154.75→€151.29
Buy
64.69%
Upside
Assigned
08/10/26
Insmed price target lowered to $175 from $179 at JPMorganInsmed price target lowered to $175 from $179 at JPMorgan
Evercore ISI Analyst forecast on DE:IM8N
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€138.32→€146.97
Buy
59.99%
Upside
Reiterated
08/07/26
Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI
Bank of America Securities Analyst forecast on DE:IM8N
Jason Zemansky
Bank of America Securities
Bank of America Securities
€183.27→€185
Buy
101.40%
Upside
Reiterated
08/07/26
Bank of America Securities Keeps Their Buy Rating on Insmed (INSM)
UBS Analyst forecast on DE:IM8N
Ashwani Verma
UBS
UBS
€143.51→€148.69
Buy
61.87%
Upside
Reiterated
08/07/26
Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS
Barclays Analyst forecast on DE:IM8N
Eliana Merle
Barclays
Barclays
€204.89
Buy
123.04%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Buy Rating on Insmed (INSM)
Roth MKM Analyst forecast on DE:IM8N
Adam Walsh
Roth MKM
Roth MKM
€183.27
Buy
99.52%
Upside
Reiterated
08/07/26
Roth MKM Reaffirms Their Buy Rating on Insmed (INSM)
TD Cowen Analyst forecast on DE:IM8N
Ritu Baral
TD Cowen
TD Cowen
€210.07
Buy
128.69%
Upside
Reiterated
08/06/26
Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating
Jefferies Analyst forecast on DE:IM8N
Faisal Khurshid
Jefferies
Jefferies
€138.32→€151.29
Buy
64.69%
Upside
Reiterated
08/06/26
Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies
RBC Capital Analyst forecast on DE:IM8N
Leonid Timashev
RBC Capital
RBC Capital
€168.58
Buy
83.52%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Their Buy Rating for Insmed (INSM)
Guggenheim Analyst forecast on DE:IM8N
Vamil Divan
Guggenheim
Guggenheim
€178.95→€177.22
Buy
92.93%
Upside
Reiterated
08/06/26
Insmed price target lowered to $205 from $207 at GuggenheimInsmed price target lowered to $205 from $207 at Guggenheim
Morgan Stanley Analyst forecast on DE:IM8N
Maxwell Skor
Morgan Stanley
Morgan Stanley
€183.27→€188.46
Buy
105.16%
Upside
Assigned
08/06/26
Morgan Stanley Sticks to Its Buy Rating for Insmed (INSM)
William Blair Analyst forecast on DE:IM8N
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Matt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story
Wells Fargo Analyst forecast on DE:IM8N
Benjamin Burnett
Wells Fargo
Wells Fargo
€139.19→€146.1
Buy
59.05%
Upside
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Qiagen (NYSE: QGEN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:IM8N
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€190.19
Buy
107.04%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)
Truist Financial Analyst forecast on DE:IM8N
Danielle Brill
Truist Financial
Truist Financial
€159.93→€168.58
Buy
83.52%
Upside
Reiterated
08/10/26
Truist Financial Remains a Buy on Insmed (INSM)
J.P. Morgan Analyst forecast on DE:IM8N
Jessica Fye
J.P. Morgan
J.P. Morgan
€154.75→€151.29
Buy
64.69%
Upside
Assigned
08/10/26
Insmed price target lowered to $175 from $179 at JPMorganInsmed price target lowered to $175 from $179 at JPMorgan
Evercore ISI Analyst forecast on DE:IM8N
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€138.32→€146.97
Buy
59.99%
Upside
Reiterated
08/07/26
Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI
Bank of America Securities Analyst forecast on DE:IM8N
Jason Zemansky
Bank of America Securities
Bank of America Securities
€183.27→€185
Buy
101.40%
Upside
Reiterated
08/07/26
Bank of America Securities Keeps Their Buy Rating on Insmed (INSM)
UBS Analyst forecast on DE:IM8N
Ashwani Verma
UBS
UBS
€143.51→€148.69
Buy
61.87%
Upside
Reiterated
08/07/26
Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS
Barclays Analyst forecast on DE:IM8N
Eliana Merle
Barclays
Barclays
€204.89
Buy
123.04%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Buy Rating on Insmed (INSM)
Roth MKM Analyst forecast on DE:IM8N
Adam Walsh
Roth MKM
Roth MKM
€183.27
Buy
99.52%
Upside
Reiterated
08/07/26
Roth MKM Reaffirms Their Buy Rating on Insmed (INSM)
TD Cowen Analyst forecast on DE:IM8N
Ritu Baral
TD Cowen
TD Cowen
€210.07
Buy
128.69%
Upside
Reiterated
08/06/26
Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating
Jefferies Analyst forecast on DE:IM8N
Faisal Khurshid
Jefferies
Jefferies
€138.32→€151.29
Buy
64.69%
Upside
Reiterated
08/06/26
Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies
RBC Capital Analyst forecast on DE:IM8N
Leonid Timashev
RBC Capital
RBC Capital
€168.58
Buy
83.52%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Their Buy Rating for Insmed (INSM)
Guggenheim Analyst forecast on DE:IM8N
Vamil Divan
Guggenheim
Guggenheim
€178.95→€177.22
Buy
92.93%
Upside
Reiterated
08/06/26
Insmed price target lowered to $205 from $207 at GuggenheimInsmed price target lowered to $205 from $207 at Guggenheim
Morgan Stanley Analyst forecast on DE:IM8N
Maxwell Skor
Morgan Stanley
Morgan Stanley
€183.27→€188.46
Buy
105.16%
Upside
Assigned
08/06/26
Morgan Stanley Sticks to Its Buy Rating for Insmed (INSM)
William Blair Analyst forecast on DE:IM8N
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Matt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story
Wells Fargo Analyst forecast on DE:IM8N
Benjamin Burnett
Wells Fargo
Wells Fargo
€139.19→€146.1
Buy
59.05%
Upside
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Qiagen (NYSE: QGEN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months
Jessica FyeJ.P. Morgan
Success Rate
16/21 ratings generated profit
76%
Average Return
+25.57%
Copying Jessica Fye's trades and holding each position for 3 Months would result in 76.19% of your transactions generating a profit, with an average return of +25.57% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
19/20 ratings generated profit
95%
Average Return
+89.25%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +89.25% per trade.
2 Years
Joseph SchwartzLeerink Partners
Success Rate
19/20 ratings generated profit
95%
Average Return
+188.47%
Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +188.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IM8N Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
8
25
33
51
42
Buy
43
30
19
8
13
Hold
2
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
53
56
52
59
55
In the current month, IM8N has received 55 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IM8N average Analyst price target in the past 3 months is 173.81.
Each month's total comprises the sum of three months' worth of ratings.

IM8N Financial Forecast

IM8N Earnings Forecast

Next quarter’s earnings estimate for IM8N is -€0.34 with a range of -€0.78 to €0.03. The previous quarter’s EPS was -€0.05. IM8N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.
Next quarter’s earnings estimate for IM8N is -€0.34 with a range of -€0.78 to €0.03. The previous quarter’s EPS was -€0.05. IM8N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Sales Forecast

Next quarter’s sales forecast for IM8N is €434.91M with a range of €396.54M to €454.75M. The previous quarter’s sales results were €369.19M. IM8N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.
Next quarter’s sales forecast for IM8N is €434.91M with a range of €396.54M to €454.75M. The previous quarter’s sales results were €369.19M. IM8N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Stock Forecast FAQ

What is DE:IM8N’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is 173.81.
    What is DE:IM8N’s upside potential, based on the analysts’ average price target?
    Insmed has 89.22% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Insmed a Buy, Sell or Hold?
          Insmed has a consensus rating of Strong Buy, which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Insmed’s share price target?
            The average share price target for Insmed is 173.81. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €210.07 ,and the lowest forecast is €146.10. The average share price target represents 89.22% Increase from the current price of €91.86.
              What do analysts say about Insmed?
              Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Insmed?
                To buy shares of DE:IM8N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.